Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations

• Material Type: 博士論文
• ISSN: 0344-5704
• Title: Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations
• Volume: 78 2
• Author/Editor: 溝口, 孝輔
• Author Heading: 溝口, 孝輔
• Publication, Distribution, etc.: Springer
• Publication Date: 2017-02-01
• Publication Date (W3CDTF): 2017-02-01
• Alternative Title: ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関
• Periodical title: Cancer Chemotherapy and Pharmacology
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2017-02-01
• Date Granted (W3CDTF): 2017-02-01
• Dissertation Number: 甲医歯薬第914号
• Degree Type: 博士(医学)
• Conferring No. (Dissertation): 甲医歯薬第914号
• Text Language Code: eng
• Subject Heading: Chemotherapy; EGFR mutations; Elimination half-life; Gefitinib; Non-small cell lung cancer; Pharmacokinetics
• Target Audience: 一般
• Note (General): Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日; Nagasaki University (長崎大学), 博士(医学) (2017-02-01)
• DOI: info:doi/10.1007/s00280-016-3097-4; https://doi.org/info:doi/10.1007/s00280-016-3097-4
• Persistent ID (NDL): info:ndljp/pid/10310784; https://dl.ndl.go.jp/pid/10310784
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2017-03-02T13:20:07+09:00
• Date Created (W3CDTF): 2020-12-21
• Format (IMT): PDF
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10069/37043; https://nagasaki-u.repo.nii.ac.jp/records/3858
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2021-03-07 再収集